Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Candid Therapeutics Inc.
Headquarters: San Diego, CA, United States of America
Website: https://www.candidrx.com/
Year Founded: 2024
Status: Private
See Emerging Company Profile .
BioCentury | Mar 26, 2025
Data Byte
China deals look beyond cancer
At least eight East-to-West licensing deals outside oncology so far this year
BioCentury | Mar 3, 2025
Deals
The dealmaking at the heart of the NewCo boom
Formed with Hummingbird assets, $187M, Callio brings trend to Singapore
BioCentury | Feb 1, 2025
Finance
Investors with deep China roots lead NewCo surge, inspiring Western VCs
Led by Orbimed, LAV, Boyu, biotech’s Asia ‘NewCo Model’ goes global
BioCentury | Jan 29, 2025
Deals
The NewCo boom signals China’s galloping speed of innovation
Companies founded in the West with Asian assets tell a story of China speed
BioCentury | Dec 17, 2024
Deals
Candid strikes trio of T cell engager partnerships for autoimmunity
BioCentry’s Deals Report also features AbbVie acquiring Nimble, Nvelop-Chroma forming nChroma, and BMS canceling Century, Immatics deals
BioCentury | Nov 14, 2024
Data Byte
Cross-border trends in uncertain times for China biotech
A new start-up model and licensing deals fueled by new modalities sustain the momentum of China biotech’s innovation engine
BioCentury | Nov 8, 2024
Editor's Commentary
China biotech and the bear: a Perspective
Deal-making with the West offers a path through uncertain times, but in what position will China biotechs emerge from the bear?
BioCentury | Nov 5, 2024
Deals
Novo to use Ascendis’ TransCon for once-monthly GLP-1R agonist
Deals report: AbbVie-EvolveImmune, Genmab-Revitope and GSK-Chimagen partner for T cell engagers
BioCentury | Oct 22, 2024
Product Development
Newco trend watch: Clusters of launches point to areas undergoing derisking
Oligo delivery to the kidney, and two emerging use cases for T cell engagers, each get newcos; most with mega-
BioCentury | Sep 12, 2024
Finance
Venture Report: Big rounds for Candid, Superluminal, PanTera
Plus: Rounds for Radiant, Vironexis, Bambusa, OrsoBio and F2G
Items per page:
1 - 10 of 13